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Both quantitative and qualitative approaches were employed. A
census of 25 radiation therapy units (both public and private
facilities) and 72 radiation therapists around the country were
carried out. Semi-structured interviews with 1500 sampled
cancer patients and in-depth interviews with 12 purposively
selected radiation therapists were conducted. RESULTS: Lacking
of vital human resources, both radiation therapists and medical
physicists, is a serious and urgent problem of the radiation
therapy services under the Ministry of Public Health (MOPH).
There was no public facility under MOPH passing the minimum
standard in terms of the appropriate amount of radiation thera-
pists, whilst only 20% of them passed the minimum standard
for medical physicists. Mal-distribution of radiation therapy
facilities favoring Bangkok and big cities, inability to pay for
traveling costs and lacking of health insurance among poor
cancer patients were crucial factors inﬂuencing equitable access
to radiation therapy services. Interviews from radiation thera-
pists support that there is an urgent need to solve the shortage
of human resources for radiation therapy services and improve
the quality of care. CONCLUSIONS: Factors of both demand
and supply sides inﬂuence the problems of inequitable access to
radiation therapy in Thailand. The removal of ﬁnancial barriers
under universal coverage can not solely solve the problem of
inequitable access to such expensive health services. Effective
short-term and long-term measures require actively participation
and concerted efforts of various stakeholders.
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OBJECTIVE: To estimate the short-term impact of adopting the
UK bowel cancer screening programme on cost and outcomes.
METHODS: The UK National Health Service (NHS) recently
announced a bowel cancer screening programme consisting of
biennial faecal occult blood testing (FOBT) to be phased in start-
ing April 2006 (25% of the potential population screened in
years 1 and 2 and 50% in year 3). Selection of this screening
strategy was based on an independent economic evaluation 
(Tappenden 2004) that ranked it fourth out of ﬁve alternative
strategies in terms of cost effectiveness. We ﬁtted a Bayesian
autoregressive age-period-cohort model to data of bowel cancer
incidence in the UK 1993–2004/5 to estimate the cost savings
and impact on outcomes resulting from phased implementation,
and from choosing a less expensive, less cost-effective screening
programme. UK costings were derived from the previous Tap-
penden 2004 analysis. RESULTS: We estimate that in the period
2006–2009, phased implementation of the chosen biennial
FOBT programme will save GBP146 million compared to full
implementation, but will also result in 2440 fewer bowel cancer
cases detected. Adoption of the most cost-effective screening
strategy would increase the number of cancers detected by 737,
and would cost GBP1.49 million less to implement than the
chosen option at the governmental phased rates in this three-year
period. When compared to no screening, it costs GBP23,679 to
detect a bowel cancer case using biennial FOBT in the age group
60–69. In the same age group, using the more cost effective strat-
egy of FSIG plus biennial FOBT it costs GBP18,534 to detect a
bowel cancer case. CONCLUSION: Affordability and service
impact appeared to be more important factors than cost effec-
tiveness in selecting a bowel cancer-screening program for the
UK.
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OBJECTIVE: The primary goal of breast cancer screening tests
is to ﬁnd cancer at an early stage before a person has any symp-
toms. Evidence suggests that screening examinations such as
mammography and clinical breast examinations (CBE) are effec-
tive in early detection of breast cancer. Physician recommenda-
tion is an important reason many women undergo screening.
This study examined the physician and patients related factors
associated with physician recommendations for breast cancer
screening in the United States (US) outpatient settings.
METHODS: This cross-sectional study used data from the
National Ambulatory Medical Care Survey (NACMS) from
1996¨C2004. Women aged °Y´40 years were included in the study
sample. Multivariate logistic regression analyses were used to
study the objectives. RESULTS: Weighted analysis indicated that
physicians performed 198 million CBEs and made 110 million
mammography recommendations over the study period
(1996–2004). Patients’ age, duration of visits, history of previ-
ous breast cancer diagnosis, and source of insurance were sig-
niﬁcant predictors of screening recommendations in this
population. Obstetricians and gynecologists were more likely to
perform a CBE and recommend mammography than other spe-
cialty physicians. CONCLUSIONS: These ﬁndings indicated that
there were certain disparities regarding the physician recom-
mendations of breast cancer screening for women in the US out-
patient settings.
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OBJECTIVES: Organized nationwide screening programme for
cervical cancer was introduced in Hungary in 2003. Women
between the ages 25–65 are invited by a personal letter and a 3
years screening interval has been applied. Before the implemen-
tation of organized screening programme there was an oppor-
tunistic screening. The aim of this study is to analyse both the
annual and three year screening rate (attendance) of the orga-
nized programme. METHODS: The data derive from the ﬁnan-
cial database of the National Health Insurance Fund
Administration (OEP) of Hungary covering the period of
2000–2005. First we calculated the annual screening rate than
we compared the three-year screening rate of two periods:
2000–2002 without and 2003–2005 with organized screening
programme. Screening is deﬁned with cytological examination of
Papanicolau smear and includes all smears taken either within
or outside of the organized programme. RESULTS: The annual
screening rate of women for all age groups varied between
15.5% and 16.8% during the 6 years between 2000–2005. The
age speciﬁc screening rate of women aged 25–64 years varied
between 21.8% and 24.3% between 2000–2005. The three-year
screening rate of women for all age groups was 31.4% in
2000–2002 and 32.9% in 2003–2005. The age speciﬁc screen-
ing rate of women in the target population aged 25–64 years
increased from 48, 45% in 2000–2002 without organized
screening programme to 52, 65% in 2003–2005 following the
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introduction of organized screening programme. CONCLU-
SIONS: The introduction of organized cervical screening pro-
gramme resulted in a 4.2% increase in screening rate in the target
age group of women aged 45–64 years. The effect of organized
cervical screening on screening rate (attendance) was very low.
In order to reduce cervical cancer mortality, screening rate (atten-
dance) must be increased.
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OBJECTIVES: Organized nationwide screening programme for
cervical cancer was introduced in Hungary in 2003. Women
between the ages 25–65 are invited by a personal letter and a 3
years screening interval has been applied. The aim of this study
is to analyse the three year screening rate (attendance or cover-
age) of the organized programme according to the age-group of
target population. METHODS: The data derive from the ﬁnan-
cial database of the National Health Insurance Fund Adminis-
tration (OEP) of Hungary covering the period of 2000–2002 and
2003–2005. We calculated the three-year screening rate for
2003–2005 according to the age-group of women. Screening is
deﬁned with cytological examination of Papanicolau smear and
includes all smears taken either within or outside of the orga-
nized programme. RESULTS: The three-year screening rate of
women aged 25–64 years increased from 48, 45% in 2000–2002
without organized screening programme to 52, 65% in
2003–2005 following the introduction of organized screening
programme. The three-year screening was the following in
2003–2005 according the age-groups: 25–29 years: 64, 24%;
30–34 years: 66%; 35–39 years: 60, 89%; 40–44 years: 55,
34%; 45–49 years: 50, 44%; 50–54 years: 49, 23%; 55–59
years: 39, 74%; 60–64 years: 31, 80%. CONCLUSIONS: After
the introduction of organized cervical screening programme we
found the highest screening rate in the age-group 30–34 years
followed by a gradually decreasing screening rates in the higher
age-groups. In order to achieve the expected mortality decline
from cervical cancer, the screening rate (attendance) of women
40–64 should be increased.
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OBJECTIVES: In modeling studies, choosing the epidemiologi-
cal data sources to best represent the future clinical situation can
be a complex issue. Here we compare two methods, a cohort
approach and a cross-sectional approach, to determine the
number of cervical cancer cases and mortalities expected to
occur, both with and without HPV-16/18 vaccination in two
countries having diverse risk factors for HPV infection and pro-
gression to cervical cancer. METHODS: Using a previously
developed Monte Carlo Discrete Event model that uses popula-
tion data to estimate the expected age-speciﬁc number of HPV
infections, cervical cancer cases and deaths, we examined the
challenges of using cross-sectional epidemiological data vs. fol-
lowing a cohort of women hypothetically over their lifetime. The
model estimated the cancer cases and mortality avoided in the
presence of vaccination (base-case: 100% vaccine uptake; no
waning of protection; 95.1% lifetime efﬁcacy against HPV
16/18). RESULTS: The number of cervical cancer cases predicted
using the cohort approach were 4584 in Poland and 37,935 in
Mexico, whereas the number of cervical cancer cases predicted
using the cross-sectional approach were 4358 in Poland and
11,059 in Mexico. Following vaccination in each country, the
number of predicted cervical cancer cases averted would differ,
depending on which method was used, between 3201 (cohort)
and 3043 (cross-sectional) in Poland, and between 22,452
(cohort) and 6545 (cross-sectional) in Mexico. CONCLUSION:
In modeling the natural history of HPV infection and cervical
cancer, one must consider whether the number of cervical cancer
cases is expected to remain stable (in line with current popula-
tion epidemiology and risk factors for HPV infection and devel-
opment of cervical cancer) in light of expected changes over time
in risk factors for the disease, including sexual behaviour, pop-
ulation demographics and screening programs. In addition, all
model assumptions and limitations should be clearly stated.
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OBJECTIVE: A Markov model simulating the long term pre-
vention effects against cervical cancer (CC) of an HPV-vaccine
has been calibrated for France. With this model we particularly
assess the difference in impact of a 20 year HPV vaccination
campaign of girls when starting vaccination with a different 
age-cohort. METHODS: The Markov model was built in
Microsoft®Excel software. It replicates the natural history of
HPV infection to CC over lifetime of a particular age-cohort of
girls. The model simulates the effect of adding vaccination to the
current screening program in terms of number of CC cases and
CC deaths avoided. All transition probabilities of the natural
history of HPV-infection to CC and the screening patterns were
obtained from literature review, expert opinion and ofﬁcial
French statistics. Screening coverage is maintained constant over
time in the model (∼60% of the French women screened every 3
years from the age of 25 to 60). Two base-case scenarios (start-
ing vaccination with different age-groups (11 to 13 versus 15 to
17-year-old + a catch up to the age of 25-year-old) were com-
pared with 100% vaccine coverage on 1st year at starting age +
each year thereafter over a period of 20 years. Extensive sensi-
tivity analysis was performed on vaccine coverage, HPV-preva-
lence, vaccine efﬁcacy. RESULTS: With 100% vaccine coverage
the model predicts a 76% reduction in CC cases (122,441 cases
avoided over lifetime) and the same reduction in CC mortality
(39,422 deaths avoided) when starting the vaccination at the age
of 11–13. With a vaccination at the age of 15–17 the reduction
is reduced to 68%. CONCLUSIONS: In both scenarios a sub-
stantial reduction in cancer cases and mortality due to vaccina-
tion will occur while keeping the current screening strategy.
However, early vaccination will lead to a higher public health
impact.
